Efficacy and safety of a novel triple combination cream compared to Kligman's trio for melasma: A 24‐week double‐blind prospective randomized controlled trial
Journal of the European Academy of Dermatology and Venereology · 2023
DOI: 10.1111/jdv.19455 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2023. Verfasst von Clémence Bertold und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, CHU Nice, Université Côte d'Azur, Nice, France. Hauptthemen laut MEDLINE: Quality of Life, Melanosis. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Kligman's trio (KT), combining hydroquinone, retinoic acid and corticosteroid, is considered as the gold standard treatment of melasma. Its efficacy has never been matched before, but it is tempered by frequent adverse effects.
Objective
To assess the efficacy and tolerance of a New Trio (NT) combination with isobutylamido‐thiazolyl‐resorcinol, retinoic acid and cortosteroid compared to KT.
Methods
We conducted a 24‐week monocentric trial, randomized, double‐blind, controlled versus KT, with 40 melasma patients. NT and KT were applied for 12 weeks and associated with the same sunscreen applied for 24 weeks. The primary endpoint was the modified Melasma Area Severity Index (mMASI) at 12 weeks. Patient quality of life was investigated using MelasQoL.
Results
After 12 weeks, KT and NT groups both demonstrated a significant improvement in mMASI, respectively −2.84 (SE 0.69, p < 0.0002) and −4.33 (SE 0.71, p < 0.0001). The mean difference between the two groups was −1.49 (IC 95% −3.52 to 0.54, p = 0.14). MelasQoL improvement was −6.66 (SE 3.29, p = 0.0515) with KT and −12.57 (SE 3.29, p = 0.0006) with NT.
Conclusion
The NT combination appears to be an effective treatment option for treating melasma and could be considered as a well‐tolerated alternative to KT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, CHU Nice, Université Côte d'Azur, Nice, France.
- Department of Clinical Research, Cimiez Hospital, CHU Nice, Université Côte d'Azur, Nice, France.
- Pharmacy Department, CHU Nice, Université Côte d'Azur, Nice, France.
- INSERM U1065, Centre Méditerranéen de Médecine Moléculaire, Université Côte d'Azur, Nice, France.
ORCID-Profile: Clémence Bertold, Tanya Singh, Thierry Passeron
Zitieren
APA
Bertold, C., Fontas, E., Singh, T., Gastaut, N., Ruitort, S., Wehrlen Pugliese, S., & Passeron, T. (2023). Efficacy and safety of a novel triple combination cream compared to Kligman's trio for melasma: A 24‐week double‐blind prospective randomized controlled trial. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19455
Vancouver
Bertold C, Fontas E, Singh T, Gastaut N, Ruitort S, Wehrlen Pugliese S, et al. Efficacy and safety of a novel triple combination cream compared to Kligman's trio for melasma: A 24‐week double‐blind prospective randomized controlled trial. Journal of the European Academy of Dermatology and Venereology. 2023. doi:10.1111/jdv.19455
BibTeX
@article{Bertold2023,
author = {Bertold, Clémence and Fontas, Eric and Singh, Tanya and Gastaut, Nadia and Ruitort, Sandra and Wehrlen Pugliese, Sylvia and Passeron, Thierry},
title = {Efficacy and safety of a novel triple combination cream compared to Kligman's trio for melasma: A 24‐week double‐blind prospective randomized controlled trial},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2023},
doi = {10.1111/jdv.19455}
}
EUVIMED